Search

everythinglearnresearchcommunity

for

Search:↓

The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.

Baricitinib helps regrow hair in teens with severe alopecia areata.

Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.

Phototherapy effectively treats certain alopecia areata types, especially if started early.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Higher MIF levels in alopecia areata patients suggest it could be a treatment target and disease predictor.

Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.

Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

JAK inhibitors are effective for treating moderate-to-severe alopecia areata.

Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Combination therapy effectively regrows hair and reduces severity in Black children with stubborn Alopecia Areata.

New hair regrowth therapies show promise but need more research.

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.

Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.

High beta-hydroxybutyrate levels may worsen hair loss in alopecia areata.

Alopecia Areata causes hair loss and needs treatments that address both physical and emotional health.

Alopecia areata may be linked to changes in body fat but not to heart or artery issues.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.

International guidelines for treating alopecia areata vary, focusing on different treatment options and related health issues.